|
| Primary information |
|---|
| ID | 10864 |
| Therapeutic ID | Th1225 |
| Protein Name | Coagulation factor X human |
| Sequence | NA
|
| Molecular Weight | 59000 |
| Chemical Formula | NA |
| Isoelectric Point | NA |
| Hydrophobicity | NA |
| Melting point | NA |
| Half-life | Following a single intravenous dose of 25 IU/kg, the mean plasma half-life (CV%) was 30.3 (22.8) hr |
| Description | NA |
| Indication/Disease | NA |
| Pharmacodynamics | The active substance in Coagadex is human factor X isolated from the plasma of blood donors. It replaces the missing factor X, thereby helping the blood to clot and giving temporary control of bleeding. |
| Mechanism of Action | Patients with hereditary factor X deficiency lack factor X, a protein needed to form the scab (blood clot) that stops wounds from bleeding. In these patients, blood clots do not form properly, resulting in longer bleeding time and poor wound healing. Blood may seep into surrounding tissues, resulting in local pain and swelling. Bleeding may also occur in internal organs. The active substance in Coagadex is human factor X isolated from the plasma of blood donors. It replaces the missing factor X, thereby helping the blood to clot and giving temporary control of bleeding. |
| Toxicity | NA |
| Metabolism | NA |
| Absorption | Following a single intravenous dose of 25 IU/kg, the mean peak plasma concentration (CV%) was 0.504 (17.2) IU/mL [FDA Label]. |
| Following a single intravenous dose of 25 IU/kg, the mean volume of distribution at steady state (CV%) was 56.3 (24.0) mL/kg [FDA Label]. |
| Clearance | Following a single intravenous dose of 25 IU/kg, the mean total body clearance was 1.35 (21.7) mL/kg/hr [FDA Label]. |
| Categories | Amino Acids, Peptides, and Proteins,Biological Factors,Blood and Blood Forming Organs,Blood Coagulation Factors,Blood Proteins,Factor X,Factor X, agonists,Factor X, antagonists & inhibitors,Hemostatics,Increased Coagulation Activity,Proteins |
| Patents Number | NA |
| Date of Issue | NA |
| Date of Expiry | NA |
| Drug Interaction | NA |
| Target | NA |
| Brand Name | Coagadex |
| Company | NA |
| Brand Description | NA |
| Prescribed For | It is used for the treatment and prevention of bleeding (including during and after an operation) in patients with hereditary factor X deficiency. Factor X deficiency is a bleeding disorder caused by lack of factor X, a protein needed for normal clotting of the blood. |
| Chemical Name | NA |
| Formulation | NA |
| Physical Appearance | powder and solvent used to make a solution |
| Route of Administration | Intravenous |
| Recommended Dosage | Dose(IU)=body weight(kg)xdesired factor X rise(IU/dL or % of normal)x0.5(IU/kg/(IU/dL) |
| Contraindication | Hypersensitivity to the active substance |
| Side Effects | The most common side effects with Coagadex (which may affect up to 1 in 10 people) are pain or redness at the injection site, fatigue (tiredness), and back pain. |
| Useful Link 1 | Link |
| Useful Link 2 | NA |
| Remarks | NA |